Keywords: Genzyme, Sanofi, Lemtrada, Aubagio, Mutliple sclerosis, USA, FDA, sBLA, US launch indicators

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio

Article | 28 January 2013

Print This

French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug Administration has accepted ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in